Author Topic: (Abst.) No evidence of beneficial effects of plasmapheresis in Tysabri-related PML  (Read 14 times)

0 Members and 0 Guests are viewing this topic.

Offline agate

  • Administrator
  • *****
  • Posts: 7514
  • Location: Pacific Northwest
From PubMed, February 24, 2017:

Quote
Neurology. 2017 Feb 22.

No evidence of beneficial effects of plasmapheresis in natalizumab-associated PML

Landi D1, De Rossi N1, Zagaglia S1, Scarpazza C1, Prosperini L1, Albanese M1, Buttari F1, Mori F1, Marfia GA1, Sormani MP1, Capra R2, Centonze D; Italian PML study group.
Collaborators (37)

Author information

1From the Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine (D.L., M.A., F.B., F.M., G.A.M., D.C.), Tor Vergata University, Rome; IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed (D.L., M.A., F.B., F.M., G.A.M., D.C.), Pozzilli; Regional Multiple Sclerosis Center (N.D.R., C.S., R.C.), ASST-Spedali Civili di Brescia, Montichiari; Neurological Clinic (S.Z.), Marche Polytechnic University, Ancona; Department of Neurology and Psychiatry (L.P.), Sapienza University, Rome; and Biostatistics Unit, Department of Health Sciences (DISSAL) (M.P.S.), University of Genoa, Italy.

2From the Multiple Sclerosis Clinical and Research Unit, Department of Systems Medicine (D.L., M.A., F.B., F.M., G.A.M., D.C.), Tor Vergata University, Rome; IRCCS Istituto Neurologico Mediterraneo (INM) Neuromed (D.L., M.A., F.B., F.M., G.A.M., D.C.), Pozzilli; Regional Multiple Sclerosis Center (N.D.R., C.S., R.C.), ASST-Spedali Civili di Brescia, Montichiari; Neurological Clinic (S.Z.), Marche Polytechnic University, Ancona; Department of Neurology and Psychiatry (L.P.), Sapienza University, Rome; and Biostatistics Unit, Department of Health Sciences (DISSAL) (M.P.S.), University of Genoa, Italy. ruggero.capra@gmail.com.

OBJECTIVE:

To examine retrospectively the effects of plasmapheresis (PLEX) on the survival and clinical outcomes of patients with multiple sclerosis (MS) and natalizumab (NTZ)-associated progressive multifocal leukoencephalopathy (PML).

METHODS:

The medical literature was searched for the terms natalizumab and progressive multifocal leukoencephalopathy. A total of 193 international and 34 Italian NTZ-PML cases were included. Clinical outcome was determined by comparing the patients' clinical status at PML diagnosis with status after PML resolution. The effects on survival and clinical outcome of PLEX, sex, age, country, pre-PML Expanded Disability Status Scale score, NTZ infusion number, prior immunosuppressant exposure, PML symptoms, PML lesion location at diagnosis, CSF JC virus status and copies, additional PML treatments and steroids, and PML immune reconstitution inflammatory syndrome (IRIS) development were investigated with both univariate and multivariate analyses.

RESULTS:

A total of 219 NTZ-PML cases were analyzed, and 184 (84%) underwent PLEX, which did not reduce the mortality risk or the likelihood of poor vs favorable outcomes. Country was predictive of mortality and poor outcome, while PML-IRIS development was predictive of poor outcome.

CONCLUSIONS:

PLEX did not improve the survival or clinical outcomes of Italian or international patients with MS and NTZ-PML, suggesting that this treatment should be performed cautiously in the future.

CLASSIFICATION OF EVIDENCE:

This study provides Class III evidence that for patients with NTZ-PML, PLEX does not improve survival. The study lacks the statistical precision to exclude an important benefit or harm of PLEX.

This abstract can be seen here.





SPMS, diagnosed 1980. Avonex 2001-2004. Copaxone 2007-2010.

 

Related Topics

  Subject / Started by Replies Last post
0 Replies
41 Views
Last post April 13, 2016, 02:06:25 pm
by agate
0 Replies
44 Views
Last post December 12, 2016, 03:31:46 pm
by agate
0 Replies
30 Views
Last post December 22, 2016, 06:00:29 pm
by agate
0 Replies
24 Views
Last post February 05, 2017, 03:57:52 pm
by agate
3 Replies
34 Views
Last post June 26, 2017, 12:14:18 pm
by agate